Retatrutide vs Tirzepatide: Data and What You Can Get

Retatrutide vs tirzepatide has a short answer and a long one. The short answer: tirzepatide is FDA approved, and a licensed provider can prescribe it today. Retatrutide is still in phase 3 trials, is not approved by any regulator, cannot be prescribed and cannot legally be compounded. No trial has compared the two head to head, and the one that will has not reported.

The rest of this page covers how the two drugs work, what their trials showed, where approval stands, what you can get, the side effects, and how to choose. PeRx prescribes compounded tirzepatide and compounded semaglutide; the semaglutide vs tirzepatide Read nextSemaglutide vs Tirzepatide: Which One Fits YouPeRx prescribes two compounded GLP-1 medications, one at $249 a month and one at $399. This is the decision guide we wish existed: what each molecule does, how the approved brands differ on their FDA labels, what the head-to-head research on those brands actually shows, and the questions a prescriber weighs before picking one for a specific patient.Read article comparison has its own guide.

Retatrutide vs Tirzepatide at a Glance

Read the weight-loss row carefully: the two figures come from different trials, run for different lengths in different populations and analyzed in different ways. They sit side by side for reference, not for ranking, and the trial section explains why.

How Retatrutide and Tirzepatide Work

Both drugs are built on the same idea. After a meal, the gut releases hormones called incretins that tell the pancreas to release insulin, slow the stomach's emptying and tell the brain the meal has landed. Tirzepatide activates two of those hormone receptors, GIP and GLP-1. Retatrutide activates the same two and adds a third, the glucagon receptor. The shared effects are what people feel on either drug: less appetite, fullness that arrives sooner and lasts longer, and insulin release that scales with blood sugar. The weight loss category page explains how GLP-1 medications work in depth.

The glucagon piece is what makes retatrutide different, and it is the least settled part. Glucagon receptor activity is thought to raise energy use and reduce liver fat; that is a hypothesis still under study, and glucagon also raises blood sugar, which is why the molecule pairs it with the two incretin receptors. More receptors does not mean more weight loss or better tolerability. It means a different balance of effects, which only trials can measure.

What the Trial Data Shows

Every number here carries its trial name, length, population and analysis type, and says whether it was peer reviewed or reported by the sponsor. That matters more in retatrutide vs tirzepatide than in most comparisons, because the same retatrutide trial has produced two different headline numbers depending on which analysis you read.

Tirzepatide Trial Results

SURMOUNT-1, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity, or overweight plus a weight-related complication, and no diabetes, to 5 mg, 10 mg or 15 mg of tirzepatide once weekly or placebo for 72 weeks. The mean change in body weight was 15.0%, 19.5% and 20.9% on the three doses against 3.1% on placebo, by the treatment-regimen estimand, so those figures already include people who stopped. Adverse events led to discontinuation in 4.3%, 7.1% and 6.2% of the tirzepatide groups and 2.6% of the placebo group.

Those results describe the product Lilly tested, which became the approved brands Mounjaro (2022) and Zepbound (2023). Compounded tirzepatide with B12, the product PeRx prescribes, was not the product in SURMOUNT-1 or any other tirzepatide trial, and those results do not describe it. The compounded tirzepatide Read nextCompounded Tirzepatide: The 2026 Rules, ExplainedCompounded tirzepatide is the same active molecule as Mounjaro and Zepbound, drawn from a multi-dose vial a state-licensed pharmacy prepared for one named patient. Everything around the molecule is different: who checked it, what the law allows, what a court has said about how it is sold, and what the safety reports show. This page walks through all of it, dated.Read article guide explains that distinction.

Retatrutide Phase 2 Results

The 2023 New England Journal of Medicine phase 2 trial randomized 338 adults with obesity, or overweight plus a weight-related condition, to 1 mg, 4 mg, 8 mg or 12 mg once weekly or placebo for 48 weeks; the primary endpoint was weight change at 24 weeks. At 48 weeks the least-squares mean change was 8.7%, 17.1%, 22.8% and 24.2% across the four dose groups against 2.1% on placebo. A phase 2 trial of 338 people is designed to pick doses, not to settle how a drug performs; the figure is peer reviewed, and it is why phase 3 was run.

Retatrutide Phase 3 Results So Far

The phase 3 program is called TRIUMPH. As of October 26, 2026, four trials have reported, two of them peer reviewed. Where both a sponsor topline number and a published number exist, both appear, because the gap between them is the clearest lesson in the retatrutide vs tirzepatide debate.

Read the TRIUMPH-1 row twice: the topline release said 28.3% on the top dose, and the NEJM paper said 25.0% by the analysis that counts everyone. Both are true. Discontinuation because of adverse events, per the sponsor, was 4.1%, 6.9% and 11.3% across the three doses against 4.9% on placebo, which is why the gap is widest at the top dose. TRIUMPH-3 and TRIUMPH-4 remain sponsor-reported, and FDA review has not started.

Why Neither Drug Can Be Called "Stronger" Yet

Put 20.9% next to 25.0% and the comparison looks decided. It is not. The populations differ, the lengths differ (72 weeks against 80), the dose schedules differ, raw and placebo-adjusted loss are different numbers that pages mix freely, and people who stop a drug change the average: a higher dropout rate on the top dose, left out of an on-treatment estimate, flatters the result, which is what the two TRIUMPH-1 numbers show.

The only fair test randomizes the same people to one drug or the other, and that trial exists. TRIUMPH-5, registered as NCT06662383, is a phase 3 double-blind study of about 800 adults with obesity assigned to retatrutide or tirzepatide, with percent change in body weight at 80 weeks as its primary endpoint. It is active, no longer recruiting, with an estimated primary completion of November 2026, and no result has been published as of October 26, 2026. Until it reports, "retatrutide is stronger than tirzepatide" is a reading of two separate trials, not a finding.

Retatrutide FDA Approval: Where It Stands Today

As of October 26, 2026, retatrutide is not approved by the FDA or by any other regulator, and Lilly's own page describes it as an investigational molecule available only to participants in its clinical trials. On July 23, 2026, Lilly said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. A planned filing is not an approval date: review takes months, approval is not guaranteed, and nobody, including Lilly, has named a date on which retatrutide will be prescribable. Lilly lists obesity with and without type 2 diabetes, severe obesity with cardiovascular disease, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and kidney outcomes, and metabolic dysfunction-associated steatotic liver disease as conditions under study, none of them approved uses.

The FDA's position on compounding is unambiguous. Its page on unapproved GLP-1 drugs, current as of October 1, 2026, states that retatrutide and cagrilintide cannot be used in compounding under federal law, because they are not components of an FDA-approved drug and have not been found safe and effective for any condition. The same page says the agency has sent warning letters to telehealth companies marketing retatrutide, to ingredient distributors selling it to compounders, to outsourcing facilities repackaging it, and to sellers whose products were falsely labeled as being for research purposes. That is a different situation from which peptides are FDA approved Read nextFDA-Approved Peptides: The Full List (2026)Peptide drugs have been FDA-approved for over forty years, from recombinant insulin in 1982 to tirzepatide in 2022. Most of the peptides people actually search for, though, are not on that list. This guide lays out every FDA-approved peptide drug with its brand names and approval year, explains the difference between an approved drug, a compounded medication, and a research chemical, and covers where the 2026 FDA compounding review left peptides like BPC-157. Current as of August 2026.Read article and will the FDA ban peptides Read nextWill the FDA Ban Peptides in 2026? What the Data SaysSearch "FDA peptide ban" and you will find panic in one direction and "they're legal again!" in the other. Both are wrong. Here is the precise, physician-reviewed answer to whether the FDA is banning peptides in 2026, and what the actual regulatory record shows.Read article , which concern how established peptides may be compounded; retatrutide cannot be compounded at all.

Is Retatrutide Available? What You Can Actually Get Today

Retatrutide Today

No licensed provider can prescribe retatrutide, and no pharmacy, compounding or otherwise, can legally dispense it. The only legal route is a registered clinical trial; ClinicalTrials.gov lists the TRIUMPH studies, and most have finished recruiting. A clinic that says it can get you retatrutide, or a compounder who says they can make it, is operating outside the law and outside any quality control. If someone offers to prescribe it, leave.

"Research" and Gray-Market Retatrutide

Vials sold online as retatrutide exist, and nobody has verified what is in them. There is no prescriber, no pharmacy, no lot testing and no recourse. The FDA describes the risks of unapproved GLP-1 products as wrong doses from self-measured vials, contamination, and adverse events that needed hospital care. In August 2026 the FDA sent warning letters to five online peptide vendors; the letter to Peak Performance Peptides, dated August 24, 2026, names retatrutide and states that labeling a product for research only, or not for human consumption, does not change the fact that it was being sold as a drug for people. Lilly says illicit retatrutide products may contain unknown ingredients, contaminants, the wrong amount of active ingredient, or the wrong ingredient entirely.

The gray market vs compounded GLP-1 Read nextGray-Market GLP-1s vs Compounded: What Testing MissesThis page is for the person doing spreadsheet math on a $44 internet vial versus a legitimate prescription. No moralizing and no scare quotes. What the three tiers of GLP-1 supply legally are, what a certificate of analysis actually proves, what it cannot, and what each route really costs per month.Read article guide explains the difference between an unregulated vial and a compounded prescription, and is it safe to buy peptides online Read nextIs It Safe to Buy Peptides Online?The honest answer is that it depends entirely on the source. "Buying peptides online" covers two opposite things: unregulated research-chemical websites, and licensed telehealth backed by a real provider and an FDA-regulated pharmacy. One of those is safe. This guide shows you how to tell them apart.Read article covers how to tell them apart. Retatrutide also belongs on the list of peptides PeRx does not prescribe Read nextPeptides to Avoid: Which Ones Are UnsafeNot every peptide sold online is one a responsible clinic should put its name on. Some have no pharmacy-grade source. Some are sold on hype with no real medical use. Some, like melanotan II, carry a documented safety signal that outweighs the benefit. Here is which peptides PeRx declines, the evidence behind those calls, and how to judge a provider by the lines it will not cross.Read article : there is no legal way to offer it, so no one at PeRx will.

Tirzepatide Today

Tirzepatide has two legal routes. The first is the brand, Mounjaro or Zepbound, prescribed by a clinician and filled by a retail pharmacy, through insurance or Lilly's own programs. The second is provider-prescribed compounded tirzepatide, prepared by a state-licensed 503A pharmacy for a named patient. Compounded tirzepatide is not FDA approved: it has not been through FDA review, and the brand's trial results do not describe it. At PeRx, a licensed provider reviews your eligibility first, a state-licensed 503A pharmacy fills the prescription, and the vial ships ready to use with no reconstitution needed. The compounded tirzepatide Read nextCompounded Tirzepatide: The 2026 Rules, ExplainedCompounded tirzepatide is the same active molecule as Mounjaro and Zepbound, drawn from a multi-dose vial a state-licensed pharmacy prepared for one named patient. Everything around the molecule is different: who checked it, what the law allows, what a court has said about how it is sold, and what the safety reports show. This page walks through all of it, dated.Read article guide has the full picture; current pricing is on its own page, and this guide gives no prices.

Tirzepatide

Available by prescription today. Tirzepatide at PeRx is compounded with vitamin B12 by a state-licensed 503A pharmacy, prescribed by a licensed provider after an eligibility check, and shipped as one ready-to-use vial per 28 days on a subscription you can cancel in one click.

It is the dual GIP and GLP-1 option in the PeRx catalog. Compounded tirzepatide is not FDA approved and is not the product studied in the brand's trials.

Compounded tirzepatide with B12, one ready-to-use vial per 28 days.

Check eligibility

Retatrutide Side Effects vs Tirzepatide Side Effects

Shared Digestive Effects

Nausea, diarrhea, constipation, vomiting and reduced appetite are the most common adverse events with both drugs. In SURMOUNT-1 they were mostly mild to moderate and clustered during dose escalation. In TRIUMPH-1, per Lilly's release, nausea was reported by 28.6%, 38.4% and 42.4% of the three retatrutide groups against 14.8% on placebo. The usual way to reduce these effects is a slow dose increase, which is how both drugs are dosed. The nausea on GLP-1 Read nextNausea & Gut Issues on GLP-1s: What HelpsGI side effects are the single biggest reason patients stop Ozempic, Wegovy, and Mounjaro. Here is why GLP-1 receptor activation hits the gut so hard, which simple changes resolve most cases, and which peptide helps when the basics have not been enough.Read article guide covers what helps.

Retatrutide-Specific Signals

Two findings in the retatrutide trials are not typical of tirzepatide. The first is dysesthesia, an altered skin sensation such as tingling or heightened sensitivity: the published TRIUMPH-2 paper reports it in 4%, 6% and 7% of the 4 mg, 9 mg and 12 mg groups against 1% on placebo, and the TRIUMPH-4 topline release describes the same signal rising with dose. The second is heart rate: in the phase 2 trial, dose-dependent increases peaked at 24 weeks and declined afterward. TRIUMPH-2 also reported low blood pressure more often with retatrutide, and discontinuation because of adverse events ran higher at the top retatrutide doses than on placebo in every TRIUMPH trial so far. Long-term safety beyond 80 weeks is unknown.

Tirzepatide Labeled Risks

Tirzepatide's risks are written on an FDA label, revised as recently as August 2026, which is itself a difference. The Zepbound label carries a boxed warning on the risk of thyroid C-cell tumors, seen in rats, with relevance to humans unknown. It lists severe gastrointestinal reactions, acute kidney injury from fluid loss, acute gallbladder disease, acute pancreatitis, serious allergic reactions, low blood sugar when combined with insulin or a sulfonylurea, diabetic retinopathy complications, and aspiration during anesthesia. It is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, anyone with multiple endocrine neoplasia syndrome type 2, and anyone with a known serious hypersensitivity to tirzepatide. A prescriber screens for every one of these. The muscle loss on GLP-1 Read nextKeep Muscle on Ozempic, Wegovy, or MounjaroUp to 40% of weight lost on GLP-1 medications is lean muscle. Here's what the research actually shows, why it happens, and which growth hormone peptides providers prescribe to protect lean mass during a caloric deficit.Read article and injection site reactions Read nextOzempic & Wegovy Injection Site Irritation: FixPainful lumps, bruising, redness, and lingering soreness are among the most common complaints from GLP-1 patients. Here is why injection sites react the way they do, how to minimize it with technique, and which peptides providers prescribe for patients with persistent nodules or slow healing.Read article guides cover two common practical concerns.

When to Seek Care

On either drug, contact a clinician promptly for severe or persistent vomiting or diarrhea, severe stomach pain, especially pain that spreads to the back, yellowing of the skin or eyes, signs of low blood sugar such as shakiness, sweating or confusion, any sign of an allergic reaction such as swelling of the face or throat, or a marked change in mood. On retatrutide, which you would only be taking inside a trial, report new skin sensations or a racing heart to the study team.

Retatrutide or Tirzepatide: Which Should You Consider Today?

Availability decides retatrutide vs tirzepatide in October 2026, because only one of the two can be prescribed. If retatrutide is approved in 2027 or later, the question changes, and the head-to-head trial should have reported by then. Until then, the choice a clinician can actually make is whether tirzepatide, semaglutide or neither fits a particular person.

Medicine is one part of a plan, not the plan. Dose belongs to the prescriber: the tirzepatide dosage chart Read nextTirzepatide Dosage Chart: Units, Strengths, ScheduleEvery tirzepatide dosage chart online shows the same six numbers, 2.5 mg to 15 mg, because they all come from one FDA label. What none of them shows is how a compounded multi-dose vial carries those numbers. At PeRx the draw never changes: 50 units once a week, every cycle, while the provider changes the strength of the vial. This page lays out the label ladder, the six vial strengths that map onto it, the units arithmetic for any concentration, and the rules for escalation, maintenance and missed doses, as of October 2026.Read article explains how the approved label's escalation works, and where to inject Read nextWhere to Inject Semaglutide and TirzepatideBoth are once-weekly subcutaneous injections, and the three standard sites are the same for each. The part that trips people up is not the site. It is that a compounded vial is not a prefilled pen, so you are drawing your own dose and reading it in syringe units. Here is the practical version.Read article covers technique. Semaglutide is the other prescribable option; the semaglutide vs tirzepatide Read nextSemaglutide vs Tirzepatide: Which One Fits YouPeRx prescribes two compounded GLP-1 medications, one at $249 a month and one at $399. This is the decision guide we wish existed: what each molecule does, how the approved brands differ on their FDA labels, what the head-to-head research on those brands actually shows, and the questions a prescriber weighs before picking one for a specific patient.Read article guide walks through that decision.

Getting Tirzepatide Through a Prescription

The path is short. You complete an eligibility check. A licensed provider reviews your medical history, your measurements, the contraindications above and your goals; PeRx does not order labs. If the provider writes a prescription, a state-licensed 503A pharmacy compounds it and the vial ships ready to use. The provider reviews again before each renewal. Compounded tirzepatide is not FDA approved. The general process is described in how to get peptides prescribed online Read nextHow to Get Peptides Prescribed OnlineThere is a legitimate way to get peptides prescribed through telehealth, and there is a gray market that skips the medicine entirely. This guide walks the real path step by step: the online assessment, the licensed provider who reviews it, the US compounding pharmacy that prepares your peptide, and the box that arrives ready to use. It also shows you how to spot the sites you should walk away from.Read article .

Frequently Asked Questions About Retatrutide and Tirzepatide

References and Review

Every trial figure on this page comes from the primary paper or the sponsor's own release, and the regulatory statements come from the FDA and from Lilly. Facts were checked on October 26, 2026, and this page will be updated when retatrutide's status changes.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. View study

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. View study

Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. Published online September 29, 2026. View study

Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a phase 3 trial. Lancet. 2026;408(10563):1455-1472. View study

Eli Lilly and Company. Retatrutide TRIUMPH-4 topline results. Press release, December 11, 2025. View study

Eli Lilly and Company. Retatrutide TRIUMPH-1 topline results. Press release, May 21, 2026. View study

Eli Lilly and Company. Retatrutide TRIUMPH-2 and TRIUMPH-3 topline results. Press release, July 23, 2026. View study

Eli Lilly and Company. What to know about retatrutide. Lilly.com, updated September 2026. View study

ClinicalTrials.gov. Retatrutide compared to tirzepatide in adults who have obesity (TRIUMPH-5). NCT06662383. View study

U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Current as of October 1, 2026. View study

U.S. Food and Drug Administration. Warning letter to Peak Performance Peptides, reference 735127. August 24, 2026. View study

Zepbound (tirzepatide) prescribing information. Eli Lilly and Company, revised August 2026. DailyMed. View study

Drugs@FDA. Mounjaro, NDA 215866, approved May 13, 2022; Zepbound, NDA 217806, approved November 8, 2023, sleep apnea supplement December 20, 2024. View study